Varex Imaging Corp
Varex Imaging designs, manufactures, sells and services X-ray imaging components and systems for medical, security and industrial inspection applications. Its two operating segments are Medical and Industrial. Medical products include X-ray tubes, flat panel and photon counting detectors, software, workstations, generators and related components used in diagnostic imaging, oncology, surgery, dental and other medical applications. Varex sells mainly to medical equipment manufacturers, which incorporate its components into their systems, and also sells replacement products and provides service and support. The Industrial segment supplies X-ray sources, detectors, software and related products for cargo and baggage screening, nondestructive testing, inspection and irradiation. It also makes industrial X-ray systems and Linatron® linear accelerators. Varex earns money from product sales, replacement components, service and support, software maintenance and service agreements. It has approximately 2,400 full-time equivalent employees at sites in North America, Europe and Asia. Varex is headquartered in Salt Lake City, Utah.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $VREX in the last 7 days.
No SEC Form 4 filings for $VREX in the last 30 days.
See all $VREX insider activity →Varex Imaging Corp (VREX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders On October 28, 2026, Varex Imaging Corporation, a Delaware corporation (the “Company”), held a special meeting of stockholders (the “Special Meeting”) to consider certain proposals related to the Agreement and Plan of
Varex Imaging (VREX) shareholders approved the merger with Teledyne Technologies, meeting a key condition. About 77% of eligible shares were represented, with a majority voting in favor. The merger requires approval by Varex's outstanding shares. Final results will be filed with the SEC within four business days.
Varex Imaging (VREX) updated its merger proxy disclosures following shareholder lawsuits and demand letters, maintaining its recommendation for the Teledyne merger. The company denies any further disclosure was required. The merger consideration and meeting schedule remain unchanged. Regulatory reviews, including HSR and NSIA, are ongoing, with the HSR waiting period set to expire November 19, 2026. Additional antitrust clearances are required in several countries.
Recent VREX coverage spans mergers & acquisitions, insider activity and corporate actions.
Approval of the merger agreement reduces deal execution risk, but closing still depends on regulatory approvals and other conditions.
Positive catalyst as the deal moves forward.
The filing adds legal uncertainty but does not alter deal economics.
Merger approval could lift Varex shares as it becomes a Teledyne subsidiary.
Insider sale by the CFO may signal reduced confidence, potentially pressuring the stock short-term.
AlphAI scores every news story that mentions VREX with an AI model for sentiment and relevance, and aggregates insider trades from Varex Imaging Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Varex Imaging Corp (VREX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders On October 28, 2026, Varex Imaging Corporation, a Delaware corporation (the “Company”), held a special meeting of stockholders (the “Special Meeting”) to consider certain proposals related to the Agreement and Plan of
Varex Imaging (VREX) shareholders approved the merger with Teledyne Technologies, meeting a key condition. About 77% of eligible shares were represented, with a majority voting in favor. The merger requires approval by Varex's outstanding shares. Final results will be filed with the SEC within four business days.
Varex Imaging (VREX) updated its merger proxy disclosures following shareholder lawsuits and demand letters, maintaining its recommendation for the Teledyne merger. The company denies any further disclosure was required. The merger consideration and meeting schedule remain unchanged. Regulatory reviews, including HSR and NSIA, are ongoing, with the HSR waiting period set to expire November 19, 2026. Additional antitrust clearances are required in several countries.
Varex Imaging Corp (VREX) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on August 10, 2026, Varex Imaging Corporation, a Delaware corporation (“Varex” or the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Teledyne Technologies Incorporated, a Delaware corporation
Maheshwari Shubham (Chief Financial Officer) sold 130,000 shares of Varex Imaging Corp (VREX) at $18.46 ($2.40M total) on 2026-09-11.
Kunkel Jay K. sold 8,121 shares of Varex Imaging Corp (VREX) at $18.48 ($0.15M total) on 2026-09-14.
Varex Imaging (VREX) shareholder Shubham Maheshwari plans to sell 130,000 shares, valued at approximately $2.4M, under Rule 144. The sale is tied to a stock option exercise and is expected to occur on September 11, 2026.
Teledyne Technologies (TDY) will acquire Varex Imaging (VREX) for $1.1 billion, including net debt and equity awards. The deal, approved by both boards, is expected to close in early 2027. Varex's X-ray technologies complement Teledyne's offerings, with minimal product overlap. The acquisition aims to accelerate Varex's product development and adoption.
Teledyne Technologies (TDY) agreed to acquire Varex Imaging (VREX) for $1.1B, or $18.90 per share in cash. The deal is expected to close in 2027. Varex's X-ray imaging tech complements Teledyne's portfolio, according to Varex's CEO. Teledyne has previously acquired firms in the healthcare sector, including Dalsa Corp. and DD-Scientific.
Teledyne (NYSE: TDY) agreed to buy Varex Imaging (NASDAQ: VREX) in an all-cash merger for $18.90 per share, valuing the deal at about $1.1 billion including net debt and equity awards. Boards approved unanimously; closing expected early 2027. Varex reported Q3 FY2026 revenue of $210.5M and GAAP net income of $15.7M.
